Germany extends organised mammography screening to women from age 45—an important final coverage decision. https://www.mattheneus.com/editorial/g-ba-mammography-screening-age-45-final-coverage-resolution-2026-10-15 #HTA #RegulatoryAffairs #HealthEconomics

Economic evaluations of personalised lifestyle care reveal both promise and a stubborn evidence gap. https://www.mattheneus.com/editorial/personalised-lifestyle-interventions-economic-evaluation-evidence-gap-2026-10-16 #HTA #HealthEconomics #EvidenceSynthesis

Germany’s G-BA found no proven added benefit for finerenone in chronic heart failure. #HTA #Pharma #HealthEconomics https://www.mattheneus.com/editorial/g-ba-finerenone-heart-failure-final-no-added-benefit-finearts-hf-2026-10-15

A review of 150 oncology cost-effectiveness models exposes a reproducibility gap—and why decision-makers should care. #HTA #HealthEconomics #EvidenceSynthesis https://www.mattheneus.com/editorial/oncology-cost-effectiveness-model-reproducibility-gap-2026-10-16

Poland advises against Xiaflex import reimbursement for Peyronie’s disease after evidence and cost review. #HTA #HealthEconomics https://www.mattheneus.com/editorial/aotmit-xiaflex-peyronies-targeted-import-negative-position-cost-2026-10-12

Constant transition risks can mislead prostate cancer models. See when time-inhomogeneous transitions are more credible. https://www.mattheneus.com/editorial/prostate-cancer-time-inhomogeneous-markov-transition-risk-validation-2026-10-16 #HTA #HealthEconomics

After OxyContin was reformulated in 2010 to make it harder to abuse, users switched to heroin. Using state differences in misuse before the reformulation, mdinardi.bsky.social shows that heroin treatment admissions rose 68% by 2015. www.journals.uchicago.edu/doi/10.1086/744527 #HealthEconomics

Poland’s HTA agency rejects Koselugo reimbursement for adults with NF1 after reviewing clinical and cost-effectiveness evidence. https://www.mattheneus.com/editorial/aotmit-koselugo-adult-nf1-non-recommendation-komet-cost-effectiveness-2026-10-14 #HTA #HealthEconomics #Pharma

📣 Planning to submit an abstract to the IHEA 2027 Congress in Santiago, Chile?

📅 Date: October 26, 2026
⏰ Time: 1:00–2:00 PM UTC
🔗 Register here: www.healtheconomics.org/event/ihea-2... [https://healtheconomics.org]

#IHEA2027 #HealthEconomics #UniversalHealthCoverage #IHEA #ResearchNetworking

📣 New Value in Health call for papers! 📣

Editors seek papers on the theme Evaluating Genomic and Precision Medicine.

More info here: https://ow.ly/wpW150ZXgI2

#HEOR #HealthEconomics #Genomics #Healthcare

Poland backs Basecal 200 reimbursement for six rare metabolic disorders. https://www.mattheneus.com/editorial/aotmit-basecal-200-protein-free-formula-six-acidurias-reimbursement-consent-2026-10-12 #HTA #HealthEconomics #RegulatoryAffairs

Evidence is not useful merely because it is technically correct. Health economics teams need a decision-use test for every output. https://www.mattheneus.com/editorial/ispor-heor-evidence-usability-decision-use-test-2026-10-15 #HTA #HealthEconomics #EvidenceSynthesis

UNMC's transplant program has not only saved over 10,000 lives but also generated an astounding $500 million for Nebraska's economy!

Learn more here

#NE #CommunityImpact #CitizenPortal #LivingDonation #HealthEconomics

🌍 September was an incredible month of community learning!

Our Special Interest Groups (SIGs) hosted 8 webinars, bringing together 780+ attendees.

📺 Missed a webinar? Watch the recordings: www.youtube.com/@healthecono...

#IHEA #HealthEconomics #Webinars #CommunityLearning

A digital diabetes value case can look compelling in year one—but cost-effectiveness depends on what happens when effects wane. https://www.mattheneus.com/editorial/digital-diabetes-matched-cohort-effect-waning-cost-effectiveness-2026-10-14 #HTA #RWE #HealthEconomics

Iron deficiency may shift HbA1c enough to distort evidence thresholds. #HTA #EvidenceSynthesis #HealthEconomics https://www.mattheneus.com/editorial/biochemia-medica-iron-deficiency-hba1c-false-elevation-meta-analysis-2026-10-15

HPV vaccine cost-effectiveness evidence doesn’t travel unchanged.
https://www.mattheneus.com/editorial/hpv-vaccination-economic-evaluation-transferability-price-threshold-screening-context-2026-10-14
#HTA #HealthEconomics #EvidenceSynthesis

Software reversals aren’t always real preference inconsistency. A Nigerian child health valuation study shows why. https://www.mattheneus.com/editorial/nigeria-child-health-state-valuation-software-reversal-preference-inconsistency-2026-10-13 #HTA #HealthEconomics

🤝 Upcoming Networking & Mentoring Event

📅 October 21, 2026
🕛 12:00 – 1:00 PM UTC + 0

🔗 Register for the session: www.healtheconomics.org/event/networ...

Submit your abstract here: docs.google.com/spreadsheets...

#Networking #Mentoring #HealthEconomics #HealthPolicy #HealthResearch

Highest mean net benefit doesn’t always mean most often optimal. Why the distinction matters in HTA decisions.
https://www.mattheneus.com/editorial/rims1-gastric-surveillance-mean-net-benefit-probability-optimal-2026-10-11
#HTA #HealthEconomics